Identification
NamePazopanib
Accession NumberDB06589
TypeSmall Molecule
GroupsApproved
Description

Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

Structure
Thumb
Synonyms
GW 78603
Pazopanibum
External IDs GW-786034 / GW786034
Product Ingredients
IngredientUNIICASInChI KeyDetails
Pazopanib Hydrochloride33Y9ANM545 635702-64-6MQHIQUBXFFAOMK-UHFFFAOYSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VotrientTablet400 mgOralNovartisNot applicableNot applicableCanada
VotrientTablet, film coated400 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet, film coated200 mg/1OralNovartis2016-07-12Not applicableUs
VotrientTablet, film coated200 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet, film coated400 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet200 mgOralNovartis2010-08-13Not applicableCanada
VotrientTablet, film coated200 mgOralNovartis Europharm Limited2010-06-14Not applicableEu
VotrientTablet, film coated200 mg/1OralGlaxosmithkline Inc2009-10-19Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII7RN5DR86CK
CAS number444731-52-6
WeightAverage: 437.518
Monoisotopic: 437.163393705
Chemical FormulaC21H23N7O2S
InChI KeyCUIHSIWYWATEQL-UHFFFAOYSA-N
InChI
InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)
IUPAC Name
5-({4-[(2,3-dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl}amino)-2-methylbenzene-1-sulfonamide
SMILES
CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1
Pharmacology
Indication

Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy)

Structured Indications
Pharmacodynamics

Pazopanib is a synthetic indazolylpyrimidine and reaches steady state concentrations of >15 μg/ml. This concentration is high enough to observe maximal inhibition of VEGFR2 phosphorylation and some anti-tumour activity (concentration required to inhibit receptors is 0.01 - 0.084 μmol/L). A reduction in tumour blood flow, increased tumour apoptosis, inhibition of tumour growth, reduction in tumour interstitial fluid pressure, and hypoxia in cancer cells can be observed in patients receiving treatment.

Mechanism of action

Pazopanib is a second-generation multitargeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumour blood vessel for tumour survival and growth.

TargetKindPharmacological actionActionsOrganismUniProt ID
Vascular endothelial growth factor receptor 1Proteinyes
inhibitor
HumanP17948 details
Vascular endothelial growth factor receptor 2Proteinyes
inhibitor
HumanP35968 details
Vascular endothelial growth factor receptor 3ProteinyesNot AvailableHumanP35916 details
Platelet-derived growth factor receptor alphaProteinyes
inhibitor
HumanP16234 details
Platelet-derived growth factor receptor betaProteinyes
inhibitor
HumanP09619 details
Mast/stem cell growth factor receptor KitProteinyes
inhibitor
HumanP10721 details
Fibroblast growth factor receptor 3Proteinunknown
inhibitor
HumanP22607 details
Tyrosine-protein kinase ITK/TSKProteinunknown
inhibitor
HumanQ08881 details
Fibroblast growth factor 1Proteinunknown
inhibitor
HumanP05230 details
SH2B adapter protein 3Proteinunknown
inhibitor
HumanQ9UQQ2 details
Related Articles
Absorption

Absorption of pazopanib in cancer patients is slow and incomplete. In patients with solid tumour, over a dose range of 50-2000 mg, absorption is nonlinear. Significant accumulation of pazopanib can also be observed in patients receiving 800 mg once daily for 22 days. Crushing tablets may increase exposure (increase in Cmax and AUC, while Tmax decreases by 2 hours). Bioavailability, oral tablet 800 mg, cancer patient = 21%; Bioavailability may be low due to incomplete absorption from the gastrointestinal tract. The major circulating component of the drug in the systemic is pazopanib, and not its metabolites. Mean maximum plasma concentration= 58.1 µg/mL; Mean AUC= 1037 µg · h/mL;

Volume of distribution

Vd steady state, IV administration 5 mg, cancer patient = 11.1 L (range of 9.15 - 13.4)

Protein binding

>99% protein bound, independent of concentrations over a range of 10-100 μg/mL.

Metabolism

Metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8. Metabolites are less active than pazopanib (10 to 20-fold less active). Three of its metabolites can be observed in the systemic and account for <10% of plasma radioactivity.

Route of elimination

Primarily excreted via feces (82.2%) and to a negligible extent via urine (<4%) in cancer patients. Most of the administered dose is excreted unchanged. Approximately 10% of dose are oxidative metabolites and are mostly eliminated via the feces.

Half life

35 hours. Oral absorption is not the rate limiting step of elimination from the plasma.

Clearance

CL, cancer patient, IV administration 5 mg = 4mL/min Half of the absorbed dose is cleared via oxidative metabolism.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
UDP-glucuronosyltransferase 1-1UGT1A1*28(TA;TA)TA pair insertion ADR Directly Studiedhyperbilirubinemia Details
HLA class I histocompatibility antigen protein P5HLA-B*57:01(G;G)G allele ADR Directly StudiedIncreased risk of liver injury due to alanine transaminase going above upper limit of normal by 3-5x. Details
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Pazopanib can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Pazopanib can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved
AfatinibThe serum concentration of Pazopanib can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Pazopanib can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Pazopanib can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Pazopanib can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Pazopanib can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
Aluminum hydroxideThe serum concentration of Pazopanib can be decreased when it is combined with Aluminum hydroxide.Approved
AmantadineThe serum concentration of Pazopanib can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Pazopanib can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Pazopanib can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Pazopanib can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Pazopanib can be increased when it is combined with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Pazopanib.Approved
AmprenavirThe serum concentration of Pazopanib can be increased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Pazopanib can be increased when it is combined with Amsacrine.Approved
AnagrelidePazopanib may increase the QTc-prolonging activities of Anagrelide.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
AprepitantThe serum concentration of Pazopanib can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Pazopanib.Approved, Investigational
Arsenic trioxidePazopanib may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPazopanib may increase the QTc-prolonging activities of Artemether.Approved
AsenapineThe serum concentration of Pazopanib can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Pazopanib can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Pazopanib can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Pazopanib can be increased when it is combined with Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Pazopanib.Approved
AtorvastatinThe serum concentration of Pazopanib can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Pazopanib can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Pazopanib can be increased when it is combined with Azithromycin.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Pazopanib.Investigational
BedaquilinePazopanib may increase the QTc-prolonging activities of Bedaquiline.Approved
BenzocaineThe serum concentration of Pazopanib can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Pazopanib can be decreased when combined with Betaxolol.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pazopanib.Approved, Investigational
BexaroteneThe serum concentration of Pazopanib can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Pazopanib can be increased when it is combined with Biperiden.Approved
Bismuth SubcitrateThe serum concentration of Pazopanib can be decreased when it is combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Pazopanib can be increased when it is combined with Boceprevir.Approved, Investigational
BortezomibBortezomib may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
BosentanThe serum concentration of Pazopanib can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Pazopanib can be increased when it is combined with Bosutinib.Approved
BromocriptineThe serum concentration of Pazopanib can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Pazopanib can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Pazopanib can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Pazopanib.Approved
BuspironeThe serum concentration of Pazopanib can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Pazopanib can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Pazopanib can be increased when it is combined with Caffeine.Approved
Calcium CarbonateThe serum concentration of Pazopanib can be decreased when it is combined with Calcium carbonate.Approved
CanagliflozinThe serum concentration of Pazopanib can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Pazopanib can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Pazopanib can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Pazopanib can be increased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Pazopanib can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Pazopanib can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Pazopanib can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pazopanib can be increased when it is combined with Ceritinib.Approved
CerivastatinCerivastatin may increase the hepatotoxic activities of Pazopanib.Withdrawn
ChloroquineThe serum concentration of Pazopanib can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Pazopanib can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Pazopanib can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholecalciferolThe metabolism of Pazopanib can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Pazopanib can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Pazopanib can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Pazopanib can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Pazopanib can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Pazopanib can be decreased when combined with Cinacalcet.Approved
CiprofloxacinThe serum concentration of Pazopanib can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CisapridePazopanib may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Pazopanib can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Pazopanib can be increased when it is combined with Clarithromycin.Approved
ClemastineThe metabolism of Pazopanib can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Pazopanib can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Pazopanib can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Pazopanib can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClopidogrelThe metabolism of Pazopanib can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClotrimazoleThe serum concentration of Pazopanib can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Pazopanib.Approved
CobicistatThe serum concentration of Pazopanib can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pazopanib can be decreased when combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Pazopanib can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Pazopanib can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Pazopanib can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Pazopanib can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Pazopanib can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Pazopanib can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pazopanib can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pazopanib can be increased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Pazopanib can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Pazopanib can be increased when it is combined with Dactinomycin.Approved
DaidzinThe serum concentration of Pazopanib can be increased when it is combined with Daidzin.Experimental
DarifenacinThe metabolism of Pazopanib can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Pazopanib can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Pazopanib can be increased when it is combined with Dasabuvir.Approved
DasatinibThe serum concentration of Pazopanib can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Pazopanib can be increased when it is combined with Daunorubicin.Approved
DeferasiroxThe serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Pazopanib.Approved
DelavirdineThe metabolism of Pazopanib can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pazopanib.Approved
DesfluraneDesflurane may increase the QTc-prolonging activities of Pazopanib.Approved
DesipramineThe serum concentration of Pazopanib can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pazopanib.Approved
DesloratadineThe serum concentration of Pazopanib can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Pazopanib can be increased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexlansoprazoleThe serum concentration of Pazopanib can be decreased when it is combined with TAK-390MR.Approved
DextromethorphanThe serum concentration of Pazopanib can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Pazopanib can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylstilbestrolThe serum concentration of Pazopanib can be increased when it is combined with Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pazopanib.Approved
DigoxinThe serum concentration of Pazopanib can be increased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Pazopanib can be increased when it is combined with Diltiazem.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Pazopanib.Approved
DipyridamoleThe serum concentration of Pazopanib can be increased when it is combined with Dipyridamole.Approved
DisopyramidePazopanib may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Pazopanib.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Pazopanib.Approved
DomperidonePazopanib may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Pazopanib can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Pazopanib can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Pazopanib can be increased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Pazopanib can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Pazopanib can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Pazopanib can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
DuloxetineThe metabolism of Pazopanib can be decreased when combined with Duloxetine.Approved
EfavirenzThe serum concentration of Pazopanib can be decreased when it is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Pazopanib can be increased when it is combined with Elacridar.Investigational
ElbasvirThe serum concentration of Pazopanib can be increased when it is combined with Elbasvir.Approved
EliglustatPazopanib may increase the QTc-prolonging activities of Eliglustat.Approved
EltrombopagThe serum concentration of Pazopanib can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Pazopanib can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Pazopanib can be increased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Pazopanib can be decreased when it is combined with Epinastine.Approved, Investigational
ErgonovineThe serum concentration of Pazopanib can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Pazopanib can be increased when it is combined with Ergotamine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
ErlotinibThe serum concentration of Pazopanib can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Pazopanib can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramPazopanib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Pazopanib can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Pazopanib can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Pazopanib can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Pazopanib can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Pazopanib can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Pazopanib can be increased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Pazopanib can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Pazopanib can be increased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Pazopanib.Approved
FamotidineThe serum concentration of Pazopanib can be decreased when it is combined with Famotidine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Pazopanib.Approved
FelodipineThe serum concentration of Pazopanib can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Pazopanib can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Pazopanib can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Pazopanib can be increased when it is combined with Fidaxomicin.Approved
FingolimodPazopanib may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Pazopanib.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Pazopanib.Approved
FluconazoleThe serum concentration of Pazopanib can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Pazopanib can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Pazopanib can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Pazopanib can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Pazopanib can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinFluvastatin may increase the hepatotoxic activities of Pazopanib.Approved
FluvoxamineThe serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
FosamprenavirThe metabolism of Pazopanib can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pazopanib can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Pazopanib.Approved
FosphenytoinThe serum concentration of Pazopanib can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Pazopanib can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Pazopanib is combined with G17DT.Investigational
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Pazopanib.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Pazopanib.Approved
GefitinibThe serum concentration of Pazopanib can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Pazopanib can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
GenisteinThe serum concentration of Pazopanib can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Pazopanib can be increased when it is combined with Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Pazopanib.Approved
Gramicidin DThe serum concentration of Pazopanib can be increased when it is combined with Gramicidin D.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
GrepafloxacinThe serum concentration of Pazopanib can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Pazopanib can be increased when it is combined with Haloperidol.Approved
HesperetinThe serum concentration of Pazopanib can be increased when it is combined with Hesperetin.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Pazopanib.Approved
HydrocodoneThe serum concentration of Hydrocodone can be increased when it is combined with Pazopanib.Approved, Illicit
HydrocortisoneThe serum concentration of Pazopanib can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Pazopanib.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
IbutilidePazopanib may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Pazopanib can be increased when it is combined with Idelalisib.Approved
IloperidonePazopanib may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Pazopanib can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Pazopanib can be increased when it is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pazopanib.Approved
IndapamideIndapamide may increase the QTc-prolonging activities of Pazopanib.Approved
IndinavirThe serum concentration of Pazopanib can be increased when it is combined with Indinavir.Approved
IndomethacinThe serum concentration of Pazopanib can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Pazopanib is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pazopanib is combined with INGN 225.Investigational
IrbesartanThe metabolism of Pazopanib can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Pazopanib.Approved, Investigational
IsavuconazoniumThe serum concentration of Pazopanib can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
IsoniazidThe metabolism of Pazopanib can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Pazopanib.Approved
ItraconazoleThe serum concentration of Pazopanib can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Pazopanib.Approved
IvacaftorThe serum concentration of Pazopanib can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Pazopanib can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Pazopanib can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Pazopanib can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Pazopanib can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Pazopanib is combined with Leflunomide.Approved, Investigational
LenvatinibPazopanib may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
LevofloxacinThe serum concentration of Pazopanib can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Pazopanib can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Pazopanib can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Pazopanib can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Pazopanib can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Pazopanib can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the QTc-prolonging activities of Pazopanib.Approved
LomitapideThe serum concentration of Pazopanib can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Pazopanib can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Pazopanib can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Pazopanib can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Pazopanib can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Pazopanib can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Pazopanib can be increased when it is combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pazopanib can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pazopanib can be decreased when it is combined with Lumacaftor.Approved
LumefantrinePazopanib may increase the QTc-prolonging activities of Lumefantrine.Approved
MagaldrateThe serum concentration of Pazopanib can be decreased when it is combined with Magaldrate.Withdrawn
Magnesium carbonateThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium carbonate.Approved
Magnesium HydroxideThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium hydroxide.Approved
Magnesium oxideThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium oxide.Approved
Magnesium TrisilicateThe serum concentration of Pazopanib can be decreased when it is combined with Magnesium Trisilicate.Approved
MaprotilineThe serum concentration of Pazopanib can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Pazopanib can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Pazopanib can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Pazopanib can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Pazopanib can be increased when it is combined with Meprobamate.Approved, Illicit
MethadoneThe serum concentration of Pazopanib can be increased when it is combined with Methadone.Approved
MethanthelineThe serum concentration of Pazopanib can be decreased when it is combined with Methantheline.Approved
MethotrimeprazineThe metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.Approved
MetiamideThe serum concentration of Pazopanib can be decreased when it is combined with Metiamide.Experimental
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
MetoprololThe serum concentration of Pazopanib can be increased when it is combined with Metoprolol.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pazopanib.Approved
MevastatinMevastatin may increase the hepatotoxic activities of Pazopanib.Experimental
MexiletineThe metabolism of Pazopanib can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Pazopanib can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Pazopanib can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Pazopanib can be increased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Pazopanib can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Pazopanib.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Pazopanib.Approved
MitomycinThe serum concentration of Pazopanib can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Pazopanib can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Pazopanib can be increased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Pazopanib can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Pazopanib.Approved
MorphineThe serum concentration of Pazopanib can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
NafcillinThe serum concentration of Pazopanib can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Pazopanib can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Pazopanib can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.Approved, Investigational
NefazodoneThe serum concentration of Pazopanib can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Pazopanib can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Pazopanib can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Pazopanib can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Pazopanib can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Pazopanib can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Pazopanib can be increased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Pazopanib can be increased when it is combined with Nilotinib.Approved, Investigational
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Pazopanib.Approved
NisoldipineThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Pazopanib can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Pazopanib can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Pazopanib can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe serum concentration of Pazopanib can be decreased when it is combined with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pazopanib.Approved
NovobiocinThe serum concentration of Pazopanib can be increased when it is combined with Novobiocin.Approved, Vet Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Pazopanib.Approved
OlanzapineThe serum concentration of Pazopanib can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe metabolism of Pazopanib can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Pazopanib.Experimental
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pazopanib.Approved
OmeprazoleThe serum concentration of Pazopanib can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Pazopanib.Approved
OsimertinibThe serum concentration of Pazopanib can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pazopanib.Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
P-NitrophenolThe serum concentration of Pazopanib can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Pazopanib can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Pazopanib can be increased when it is combined with Palbociclib.Approved
PaliperidonePazopanib may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Pazopanib can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Pazopanib can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Pazopanib can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Pazopanib can be increased when it is combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Pazopanib can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Pazopanib.Approved
PentobarbitalThe serum concentration of Pazopanib can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Pazopanib.Approved
PerindoprilThe serum concentration of Pazopanib can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Pazopanib can be decreased when it is combined with Phenobarbital.Approved
PhenytoinThe serum concentration of Pazopanib can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pazopanib.Approved, Investigational
PimozideThe serum concentration of Pazopanib can be increased when it is combined with Pimozide.Approved
PioglitazoneThe metabolism of Pazopanib can be decreased when combined with Pioglitazone.Approved, Investigational
PitavastatinPitavastatin may increase the hepatotoxic activities of Pazopanib.Approved
Platelet Activating FactorThe serum concentration of Pazopanib can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Pazopanib can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Pazopanib can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pazopanib can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Pazopanib can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Pazopanib can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Pazopanib.Approved
PrimidoneThe serum concentration of Pazopanib can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Pazopanib can be increased when it is combined with Probenecid.Approved
ProcainamidePazopanib may increase the QTc-prolonging activities of Procainamide.Approved
ProgesteroneThe serum concentration of Pazopanib can be increased when it is combined with Progesterone.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
PromethazineThe serum concentration of Pazopanib can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Pazopanib can be increased when it is combined with Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Pazopanib can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Pazopanib can be increased when it is combined with Protriptyline.Approved
QuercetinThe serum concentration of Pazopanib can be increased when it is combined with Quercetin.Experimental
QuetiapinePazopanib may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Pazopanib can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Pazopanib can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Pazopanib can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Pazopanib can be increased when it is combined with Rabeprazole.Approved, Investigational
RanitidineThe serum concentration of Pazopanib can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Pazopanib can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Pazopanib can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Pazopanib can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Pazopanib can be increased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Pazopanib can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Pazopanib can be increased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Pazopanib can be decreased when it is combined with Rifapentine.Approved
RilpivirineThe serum concentration of Pazopanib can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Pazopanib is combined with CDX-110.Investigational
RisperidoneRisperidone may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
RitonavirThe serum concentration of Pazopanib can be increased when it is combined with Ritonavir.Approved, Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Pazopanib.Approved
RolapitantThe serum concentration of Pazopanib can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Pazopanib can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Pazopanib can be decreased when combined with Rosiglitazone.Approved, Investigational
RosuvastatinRosuvastatin may increase the hepatotoxic activities of Pazopanib.Approved
Roxatidine acetateThe serum concentration of Pazopanib can be decreased when it is combined with Roxatidine acetate.Approved
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pazopanib.Approved
SaquinavirThe serum concentration of Pazopanib can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineThe serum concentration of Pazopanib can be increased when it is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Pazopanib can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Pazopanib can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Pazopanib can be increased when it is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
SildenafilThe metabolism of Pazopanib can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pazopanib can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Pazopanib can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Pazopanib can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pazopanib.Approved
SirolimusThe serum concentration of Pazopanib can be increased when it is combined with Sirolimus.Approved, Investigational
SolifenacinSolifenacin may increase the QTc-prolonging activities of Pazopanib.Approved
SorafenibThe serum concentration of Pazopanib can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolPazopanib may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneThe serum concentration of Pazopanib can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Pazopanib is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Pazopanib can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StaurosporineThe serum concentration of Pazopanib can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Pazopanib can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Pazopanib can be decreased when it is combined with Streptozocin.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Pazopanib.Approved
SulfasalazineThe serum concentration of Pazopanib can be increased when it is combined with Sulfasalazine.Approved
SulfinpyrazoneThe serum concentration of Pazopanib can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
SumatriptanThe serum concentration of Pazopanib can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Pazopanib can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Pazopanib can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Pazopanib can be increased when it is combined with Tacrolimus.Approved, Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Pazopanib.Approved, Investigational
TamoxifenThe serum concentration of Pazopanib can be increased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Pazopanib can be increased when it is combined with Taurocholic Acid.Experimental
TelaprevirThe serum concentration of Pazopanib can be increased when it is combined with Telaprevir.Withdrawn
TelavancinTelavancin may increase the QTc-prolonging activities of Pazopanib.Approved
TelithromycinThe serum concentration of Pazopanib can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Pazopanib can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Pazopanib can be increased when it is combined with Temsirolimus.Approved
Tenofovir disoproxilThe metabolism of Pazopanib can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Pazopanib can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Pazopanib can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pazopanib.Approved
TerfenadineThe serum concentration of Pazopanib can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Pazopanib can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Pazopanib can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazinePazopanib may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Pazopanib can be decreased when combined with Theophylline.Approved
ThioridazinePazopanib may increase the QTc-prolonging activities of Thioridazine.Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pazopanib.Approved
TicagrelorThe serum concentration of Pazopanib can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Pazopanib can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Pazopanib can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Pazopanib.Approved
TocilizumabThe serum concentration of Pazopanib can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPazopanib may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolterodineTolterodine may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TolvaptanThe serum concentration of Pazopanib can be increased when it is combined with Tolvaptan.Approved
TopotecanThe serum concentration of Pazopanib can be increased when it is combined with Topotecan.Approved, Investigational
ToremifenePazopanib may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranylcypromineThe metabolism of Pazopanib can be decreased when combined with Tranylcypromine.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pazopanib.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
TrifluoperazineThe serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Pazopanib can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Pazopanib can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Pazopanib can be increased when it is combined with Trimipramine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pazopanib.Approved, Vet Approved
UbidecarenoneCoenzyme Q10 may increase the hepatotoxic activities of Pazopanib.Experimental
VandetanibThe serum concentration of Pazopanib can be increased when it is combined with Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Pazopanib.Approved
VemurafenibThe serum concentration of Pazopanib can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Pazopanib can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Pazopanib can be increased when it is combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Pazopanib.Approved
VinblastineThe serum concentration of Pazopanib can be increased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Pazopanib can be increased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Pazopanib can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Pazopanib can be increased when it is combined with Vismodegib.Approved
VoriconazoleThe serum concentration of Pazopanib can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Pazopanib.Approved, Investigational
ZimelidineThe serum concentration of Pazopanib can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidonePazopanib may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolPazopanib may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid drinking grapefruit juice as it is a CYP 3A4 inhibitor and will increase exposure of pazopanib
  • Bioavailability increases with food. Take pazopanib on empty stomach.
References
Synthesis ReferenceNot Available
General References
  1. Sonpavde G, Hutson TE, Sternberg CN: Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert Opin Investig Drugs. 2008 Feb;17(2):253-61. doi: 10.1517/13543784.17.2.253. [PubMed:18230058 ]
  2. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]
  3. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165 ]
  4. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
External Links
ATC CodesL01XE11 — Pazopanib
AHFS Codes
  • 10:00
PDB EntriesNot Available
FDA labelDownload (593 KB)
MSDSDownload (70.4 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentRenal Cell Adenocarcinoma1
0RecruitingTreatmentRenal Cell Adenocarcinoma1
1Active Not RecruitingOtherCholangiocarcinomas / Soft-Tissue Sarcoma / Thyroid Cancers / Tumors, Solid1
1Active Not RecruitingOtherTumors, Solid1
1Active Not RecruitingTreatmentAdvanced Cancers1
1Active Not RecruitingTreatmentAdvanced Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentBreast Cancer - Female / Unspecified Adult Solid Tumor - Protocol Specific1
1Active Not RecruitingTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma, Colorectal / Carcinoma, Pancreatic / Malignant Neoplasm of Prostate / Melanoma / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Tumors, Solid1
1Active Not RecruitingTreatmentClear-cell Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentMetastatic Renal Cell Carcinoma1
1Active Not RecruitingTreatmentRenal Cancers / Tumors, Solid1
1Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentSolid Neoplasms1
1Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedScreeningTumors, Solid1
1CompletedSupportive CareAge Related Macular Degeneration (ARMD)1
1CompletedTreatmentAdvanced Cancers1
1CompletedTreatmentAdvanced Solid Tumours / Cancers / Lung Cancer, Non-Small Cell1
1CompletedTreatmentCancer, Advanced1
1CompletedTreatmentCancers1
1CompletedTreatmentCancers / Renal Cell Adenocarcinoma2
1CompletedTreatmentCarcinoma, Hepatic Cell / Liver Cancer1
1CompletedTreatmentCentral nervous system neoplasms malignant NEC / Genitourinary Neoplasms Malignancy and Gender Unspecified / Malignant Neoplasm of Breast / Malignant Neoplasm of Gastrointestinal Tract / Malignant Neoplasm of Thorax / Melanoma / Neoplasms, Head and Neck1
1CompletedTreatmentChildhood Central Nervous System Choriocarcinoma / Childhood Central Nervous System Embryonal Tumor / Childhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma / Childhood Central Nervous System Mixed Germ Cell Tumor / Childhood Central Nervous System Teratoma / Childhood Central Nervous System Yolk Sac Tumor / Metastatic Childhood Soft Tissue Sarcoma / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Central Nervous System Embryonal Tumor / Recurrent Childhood Soft Tissue Sarcoma / Recurrent Childhood Visual Pathway Glioma / Unspecified Childhood Solid Tumor, Protocol Specific1
1CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal2
1CompletedTreatmentGynecologic Tumors1
1CompletedTreatmentLung Cancer, Non-Small Cell2
1CompletedTreatmentMacular Degeneration2
1CompletedTreatmentMalignant Lymphomas / Neoplasms1
1CompletedTreatmentMalignant Neoplasm of Prostate1
1CompletedTreatmentMetastatic Cancers / Tumors, Solid1
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Breast / Solid Tumor Cancers1
1CompletedTreatmentNeoplasms, Ovarian1
1CompletedTreatmentNeoplasms / Sarcomas / Stomach Neoplasms1
1CompletedTreatmentPlaque Psoriasis / Psoriasis1
1CompletedTreatmentRecurrent Thyroid Cancer / Stage IVA Follicular Thyroid Cancer / Stage IVA Papillary Thyroid Cancer / Stage IVB Follicular Thyroid Cancer / Stage IVB Papillary Thyroid Cancer / Stage IVC Follicular Thyroid Cancer / Stage IVC Papillary Thyroid Cancer1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentRenal Cell Adenocarcinoma / Solid Tumor Cancers1
1CompletedTreatmentRenal Cell Adenocarcinoma / Tumors, Solid1
1CompletedTreatmentSoft Tissue Sarcoma (STS)1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Not Yet RecruitingTreatmentSarcomas1
1RecruitingNot AvailableCancers1
1RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer1
1SuspendedTreatmentMetastatic Disease / Renal Cell Adenocarcinoma / Soft Tissue Sarcoma (STS)1
1TerminatedPreventionCancer, Breast / Head and Neck Carcinoma / Hepatocellular Cancer / Lung Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Renal Cancers / Sarcomas1
1TerminatedTreatmentMale Breast Carcinoma / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
1TerminatedTreatmentMetastatic Breast Cancer (MBC) / Metastatic Non Small Cell Lung Cancer1
1TerminatedTreatmentMetastatic Cancers1
1Unknown StatusTreatmentMetastatic Cancer (Different Solid Tumour Types)1
1Unknown StatusTreatmentMetastatic Solid Tumors1
1WithdrawnTreatmentNeoplasms, Brain / Neuroblastomas / Sarcoma, Osteogenic / Sarcomas / Wilms' tumor1
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAdvanced Renal Cell Carcinoma1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2CompletedTreatmentAdvanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy1
1, 2CompletedTreatmentCorneal Neovascularization1
1, 2CompletedTreatmentOperable Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentOvarian Epithelial Cancer1
1, 2Enrolling by InvitationTreatmentTumors, Solid1
1, 2RecruitingTreatmentAdvanced Soft Tissue Sarcoma1
1, 2RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2RecruitingTreatmentCancer, Ovarian / Neoplasms, Ovarian1
1, 2RecruitingTreatmentClear Cell Renal Cell Carcinoma / Stage IV Renal Cell Cancer1
1, 2RecruitingTreatmentGlioblastoma Multiforme1
1, 2RecruitingTreatmentHigh Grade Sarcoma / Metastatic Leiomyosarcoma / Metastatic Malignant Peripheral Nerve Sheath Tumor / Metastatic Synovial Sarcoma / Metastatic Undifferentiated Pleomorphic Sarcoma / Myxofibrosarcoma / Recurrent Leiomyosarcoma / Recurrent Malignant Peripheral Nerve Sheath Tumor / Recurrent Synovial Sarcoma / Recurrent Undifferentiated Pleomorphic Sarcoma / Uterine Corpus Leiomyosarcoma1
1, 2RecruitingTreatmentPancreatic Alpha Cell Carcinoma / Pancreatic Beta Islet Cell Carcinoma / Pancreatic Delta Cell Carcinoma / Pancreatic G-cell Carcinoma / Recurrent Islet Cell Carcinoma1
1, 2RecruitingTreatmentTumors, Central Nervous System / Tumors, Solid1
1, 2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
1, 2TerminatedTreatmentMalignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate1
2Active Not RecruitingTreatmentAdvanced and / or Metastatic Liposarcoma1
2Active Not RecruitingTreatmentAtypical Carcinoid Tumor / Foregut Carcinoid Tumor / Hindgut Carcinoid Tumor / Lung Carcinoid Tumor / Metastatic Carcinoid Tumors / Metastatic Digestive System Neuroendocrine Tumor G1 / Midgut Carcinoid Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Regional Digestive System Neuroendocrine Tumor G11
2Active Not RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentCancer, Ovarian1
2Active Not RecruitingTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cancer1
2Active Not RecruitingTreatmentChondrosarcomas / Metastatic Chondrosarcoma1
2Active Not RecruitingTreatmentClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentHormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma1
2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2Active Not RecruitingTreatmentMetastatic Osteosarcoma / Sarcoma, Osteogenic1
2Active Not RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentRecurrent Melanoma / Stage IV Skin Melanoma1
2Active Not RecruitingTreatmentRecurrent Thyroid Gland Carcinoma / Stage III Differentiated Thyroid Gland Carcinoma / Stage III Thyroid Gland Medullary Carcinoma / Stage IVA Differentiated Thyroid Gland Carcinoma / Stage IVA Thyroid Gland Medullary Carcinoma / Stage IVA Thyroid Gland Undifferentiated (Anaplastic) Carcinoma / Stage IVB Differentiated Thyroid Gland Carcinoma / Stage IVB Thyroid Gland Medullary Carcinoma / Stage IVB Thyroid Gland Undifferentiated (Anaplastic) Carcinoma / Stage IVC Differentiated Thyroid Gland Carcinoma / Stage IVC Thyroid Gland Medullary Carcinoma / Stage IVC Thyroid Gland Undifferentiated (Anaplastic) Carcinoma / Thyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2Active Not RecruitingTreatmentRenal Cancers1
2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma3
2Active Not RecruitingTreatmentRenal Cell Carcinoma Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2Active Not RecruitingTreatmentSalivary Gland Carcinoma1
2Active Not RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2Active Not RecruitingTreatmentStage III Melanoma / Stage IV Melanoma / Unresectable Melanoma1
2Active Not RecruitingTreatmentThyroid Gland Undifferentiated (Anaplastic) Carcinoma1
2Active Not RecruitingTreatmentVon Hippel-Lindau Syndrome1
2CompletedSupportive CareLymphedema of the extremities1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2CompletedTreatmentAdult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Recurrent Adult Brain Tumor1
2CompletedTreatmentAdvanced Malignant Mesothelioma / Localized Malignant Mesothelioma / Recurrent Malignant Mesothelioma1
2CompletedTreatmentAdvanced/Metastatic Neuroendocrine Tumors1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentCancer, Breast / Male Breast Cancer / Recurrent Breast Cancer / Stage IV Breast Cancer1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Tumor of Peritoneum / Neoplasms, Ovarian1
2CompletedTreatmentCancers / Cervix Diseases / Neoplasms, Ovarian / Ovarian Epithelial Cancer / Primary Peritoneal Carcinoma / Tumors / Uterine Diseases1
2CompletedTreatmentClear Cell Renal Cell Carcinoma1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Stage I Renal Cell Cancer / Stage II Renal Cell Cancer / Stage III Renal Cell Cancer1
2CompletedTreatmentDistal Urethral Cancer / Proximal Urethral Cancer / Recurrent Bladder Cancer / Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter / Recurrent Urethral Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder / Urethral Cancer Associated With Invasive Bladder Cancer1
2CompletedTreatmentGIST1
2CompletedTreatmentGastrin-Producing Neuroendocrine Tumor / Lung Carcinoid Tumor / Metastatic Digestive System Neuroendocrine Tumor G1 / Multiple Endocrine Neoplasia Type 1 / Pancreatic Glucagonoma / Pancreatic Insulinoma / Pancreatic Polypeptide Tumor / Recurrent Digestive System Neuroendocrine Tumor G1 / Recurrent Pancreatic Neuroendocrine Carcinoma / Regional Digestive System Neuroendocrine Tumor G1 / Somatostatin-Producing Neuroendocrine Tumor1
2CompletedTreatmentGastrointestinal Stromal Tumors1
2CompletedTreatmentGliomas1
2CompletedTreatmentLiposarcoma / Metastatic Liposarcoma / Surgically Unresectable Liposarcoma1
2CompletedTreatmentLocally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers1
2CompletedTreatmentLung Cancer, Non-Small Cell1
2CompletedTreatmentLung Cancer, Non-Small Cell / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentLung Cancers1
2CompletedTreatmentMacular Degeneration2
2CompletedTreatmentMalignant Neoplasm of Stomach1
2CompletedTreatmentMultiple Myeloma (MM) / Renal Cell Adenocarcinoma1
2CompletedTreatmentNeoplasms, Breast3
2CompletedTreatmentNeoplasms, Ovarian1
2CompletedTreatmentNeoplasms, Uterine Cervix / Recurrent, IV-B Cervical cancer1
2CompletedTreatmentNeuroendocrine Tumors1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentPlatinum-resistant Advanced Ovarian Cancer1
2CompletedTreatmentRecurrent Lymphoepithelioma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2CompletedTreatmentRecurrent Prostate Cancer1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRenal Cell Adenocarcinoma2
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2Not Yet RecruitingTreatmentAdvanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma1
2Not Yet RecruitingTreatmentCentral Nervous System Neoplasms / Glioblastoma Multiforme / Glioblastomas / Gliosarcoma / Neoplasms, Brain1
2Not Yet RecruitingTreatmentClear Cell Metastatic Renal Cell Carcinoma1
2Not Yet RecruitingTreatmentRenal Cell Adenocarcinoma1
2Not Yet RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2RecruitingTreatmentAdult Alveolar Soft Part Sarcoma / Adult Angiosarcoma / Adult Desmoplastic Small Round Cell Tumor / Adult Epithelioid Hemangioendothelioma / Adult Epithelioid Sarcoma / Adult Extraskeletal Myxoid Chondrosarcoma / Adult Extraskeletal Osteosarcoma / Adult Fibrosarcoma / Adult Leiomyosarcoma / Adult Liposarcoma / Adult Malignant Mesenchymoma / Adult Malignant Peripheral Nerve Sheath Tumor / Adult Rhabdomyosarcoma / Adult Synovial Sarcoma / Adult Undifferentiated Pleomorphic Sarcoma / Malignant Adult Hemangiopericytoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentAdult Angiosarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentAdult Liposarcoma / Metastatic Liposarcoma / Metastatic Osteosarcoma / Recurrent Adult Soft Tissue Sarcoma / Recurrent Liposarcoma / Recurrent Osteosarcoma / Stage IV Adult Soft Tissue Sarcoma1
2RecruitingTreatmentBiliary Carcinoma / Carcinoma of Gallbladder / Cholangiocarcinomas1
2RecruitingTreatmentCancer, Ovarian1
2RecruitingTreatmentCarcinoma of the Collecting Ducts of Bellini / Chromophobe Renal Cell Carcinoma / Kidney Medullary Carcinoma / Kidney Oncocytoma / Metastatic Renal Cell Cancer / Papillary Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Sarcomatoid Renal Cell Carcinoma / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma1
2RecruitingTreatmentExtraskeletal Myxoid Chondrosarcoma / Solitary Fibrous Tumor1
2RecruitingTreatmentHemangiosarcoma1
2RecruitingTreatmentLeiomyosarcomas1
2RecruitingTreatmentMalignant Solid Neoplasms1
2RecruitingTreatmentMetastatic Renal Cell Carcinoma1
2RecruitingTreatmentProgressive Desmoids Tumors1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentRenal Cancers1
2RecruitingTreatmentRenal Cell Adenocarcinoma1
2RecruitingTreatmentSarcomas2
2RecruitingTreatmentSarcomas / Soft Tissue Sarcoma (STS)1
2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
2RecruitingTreatmentSoft-Tissue Sarcoma1
2RecruitingTreatmentThyroid Carcinoma1
2RecruitingTreatmentTumors, Solid1
2TerminatedBasic ScienceCancer, Breast / Cancer, Ovarian / Cervical Cancers / Gastrointestinal Cancers / Glioblastomas / Lung Cancer Small Cell Lung Cancer (SCLC) / Malignant Neoplasm of Pancreas / Melanoma / Non-Small-Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Soft Tissue Sarcoma (STS)1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentDermatofibrosarcomas of DARIER FERRAND(DFSP)1
2TerminatedTreatmentEstrogen Receptor-Positive Breast Cancer / Human Epidermal Growth Factor 2 Negative Carcinoma of Breast / Male Breast Cancer / Recurrent Breast Cancer / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
2TerminatedTreatmentExtra-Adrenal Paraganglioma / Metastatic Adrenal Gland Pheochromocytoma / Paraganglioma / Recurrent Adrenal Gland Pheochromocytoma1
2TerminatedTreatmentHereditary Haemorrhagic Telangiectasia (HHT)1
2TerminatedTreatmentHormone-receptors Positive Breast Cancer1
2TerminatedTreatmentLocally Advanced Renal Cell Carcinoma / Metastatic Renal Cell Carcinoma1
2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2TerminatedTreatmentLung Cancer, Non-Small Cell1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2TerminatedTreatmentMalignant Neoplasm of Prostate1
2TerminatedTreatmentMetastatic Alveolar Soft Part Sarcoma1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentPenile Squamous Cell Carcinoma Stage IV1
2Unknown StatusTreatmentAdverse Drug Events / Renal Cell Adenocarcinoma / Self Efficacy1
2Unknown StatusTreatmentBladder (Urothelial, Transitional Cell) Cancer / Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable / Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) / Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) / Bladder Cancers1
2Unknown StatusTreatmentGastric cancer stage IV1
2Unknown StatusTreatmentGastrointestinal Stromal Tumors (GISTs)1
2Unknown StatusTreatmentGerm Cell Tumors / Measurable Disease / Relapse or Progression After 2 or 3 Chemotherapy Regimens / Relapse or Progression After High-dose Chemotherapy1
2Unknown StatusTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Unknown StatusTreatmentMelanoma1
2Unknown StatusTreatmentMetastatic Renal Cell Carcinoma1
2Unknown StatusTreatmentRelapsed or Metastatic Uterine Leiomyosarcomas or Carcinosarcomas1
2WithdrawnTreatmentCervical Cancers1
2WithdrawnTreatmentGastrointestinal Stromal Tumors1
2WithdrawnTreatmentSoft Tissue Sarcoma (STS)1
2WithdrawnTreatmentUterine Leiomyosarcoma1
2, 3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3RecruitingTreatmentAdult Fibrosarcoma / Alveolar Soft Part Sarcoma (ASPS) / Angiomatoid Fibrous Histiocytoma / Atypical Fibroxanthoma / Chondrosarcoma, Mesenchymal / Clear Cell Sarcoma of Soft Tissue / Epithelioid Malignant Peripheral Nerve Sheath Tumor / Epithelioid Sarcoma / Extraskeletal Myxoid Chondrosarcoma / Extraskeletal osteosarcomas / Fibrohistiocytic Neoplasm / Glomus Tumor of the Skin / Inflammatory Myofibroblastic Tumors / Intimal Sarcoma / Leiomyosarcomas / Liposarcoma / Low Grade Fibromyxoid Sarcoma / Low Grade Myofibroblastic Sarcoma / Malignant Cutaneous Granular Cell Tumor / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Malignant Triton Tumor / Myxofibrosarcoma / Myxoid Chondrosarcoma / Myxoinflammatory Fibroblastic Sarcoma / Nerve Sheath Neoplasm / PEComa / Pericytic Neoplasm / Plexiform Fibrohistiocytic Tumor / Sclerosing Epithelioid Fibrosarcoma / Stage IB Soft Tissue Sarcoma / Stage IIB Soft Tissue Sarcoma / Stage III Soft Tissue Sarcoma / Stage IV Soft Tissue Sarcoma / Synovial Sarcoma / Undifferentiated (Embryonal) Sarcoma / Undifferentiated High Grade Pleomorphic Sarcoma of Bone1
2, 3TerminatedTreatmentLung Cancers1
3Active Not RecruitingTreatmentCancers1
3Active Not RecruitingTreatmentNeoplasms, Ovarian1
3Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
3CompletedTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3CompletedTreatmentRenal Cell Adenocarcinoma4
3CompletedTreatmentSoft Tissue Sarcoma (STS)1
3RecruitingTreatmentAdvanced Angiosarcoma1
3RecruitingTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer1
4CompletedTreatmentCancers1
4RecruitingNot AvailableMetastatic Renal Cell Cancer1
4RecruitingTreatmentClear-cell Metastatic Renal Cell Carcinoma / Locally Advanced and/or Metastatic Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
Not AvailableActive Not RecruitingDiagnosticAdvanced Solid Tumors / Cancers1
Not AvailableActive Not RecruitingTreatmentStage IIA Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
Not AvailableCompletedNot AvailableMetastatic Renal Cell Carcinoma1
Not AvailableCompletedNot AvailableRenal Cell Adenocarcinoma3
Not AvailableCompletedDiagnosticClear Cell Renal Cell Carcinoma / Recurrent Renal Cell Cancer / Stage IV Renal Cell Cancer1
Not AvailableNot Yet RecruitingTreatmentRefractory Solid Tumors1
Not AvailableRecruitingNot AvailableSoft Tissue Sarcoma (STS)1
Not AvailableRecruitingTreatmentRefractory Solid Tumors1
Not AvailableWithdrawnTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Adenocarcinoma1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral200 mg
TabletOral400 mg
Tablet, film coatedOral200 mg/1
Tablet, film coatedOral200 mg
Tablet, film coatedOral400 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7105530 No2003-10-192023-10-19Us
US7262203 No2001-12-192021-12-19Us
US8114885 No2001-12-192021-12-19Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0433 mg/mLALOGPS
logP3.59ALOGPS
logP3.55ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)10.41ChemAxon
pKa (Strongest Basic)5.07ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area119.03 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity132.18 m3·mol-1ChemAxon
Polarizability45.41 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.8788
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.8307
P-glycoprotein inhibitor INon-inhibitor0.8126
P-glycoprotein inhibitor IIInhibitor0.5
Renal organic cation transporterNon-inhibitor0.8152
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateNon-substrate0.8008
CYP450 3A4 substrateNon-substrate0.6024
CYP450 1A2 substrateNon-inhibitor0.5
CYP450 2C9 inhibitorNon-inhibitor0.5065
CYP450 2D6 inhibitorNon-inhibitor0.7779
CYP450 2C19 inhibitorNon-inhibitor0.6811
CYP450 3A4 inhibitorNon-inhibitor0.5385
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5668
Ames testNon AMES toxic0.6543
CarcinogenicityNon-carcinogens0.8567
BiodegradationNot ready biodegradable0.9935
Rat acute toxicity2.3961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9219
hERG inhibition (predictor II)Non-inhibitor0.7129
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-052r-0118900000-097bcfa914e959e3d51aView in MoNA
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-004i-0910000000-fd84ad14c383d8fa623fView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-qTof , PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic nitrogen compounds
Sub ClassOrganonitrogen compounds
Direct ParentAlkyldiarylamines
Alternative ParentsBenzenesulfonamides / Indazoles / Benzenesulfonyl compounds / Aniline and substituted anilines / Toluenes / Aminopyrimidines and derivatives / Organosulfonamides / Imidolactams / Pyrazoles / Heteroaromatic compounds
SubstituentsAlkyldiarylamine / Benzenesulfonamide / Indazole / Benzopyrazole / Benzenesulfonyl group / Aniline or substituted anilines / Aminopyrimidine / Toluene / Pyrimidine / Imidolactam
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsaminopyrimidine, sulfonamide, indazoles (CHEBI:71219 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vegf-b-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation ...
Gene Name:
FLT1
Uniprot ID:
P17948
Molecular Weight:
150767.185 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domai...
Gene Name:
KDR
Uniprot ID:
P35968
Molecular Weight:
151525.555 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced pr...
Gene Name:
FLT4
Uniprot ID:
P35916
Molecular Weight:
152755.94 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor-activated receptor activity
Specific Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for PDGFA, PDGFB and PDGFC and plays an essential role in the regulation of embryonic development, cell proliferation, survival and chemotaxis. Depending on the context, promotes or inhibits cell proliferation and cell migration. Plays an important role in the differentiation of bone marrow-derived mesenchymal stem cells. Required for...
Gene Name:
PDGFRA
Uniprot ID:
P16234
Molecular Weight:
122668.46 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor binding
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for homodimeric PDGFB and PDGFD and for heterodimers formed by PDGFA and PDGFB, and plays an essential role in the regulation of embryonic development, cell proliferation, survival, differentiation, chemotaxis and migration. Plays an essential role in blood vessel development by promoting proliferation, migration and recruitment of peri...
Gene Name:
PDGFRB
Uniprot ID:
P09619
Molecular Weight:
123966.895 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transmembrane receptor protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, KIT can activate several signaling pathways. Phosphorylates PIK3R1, PLCG1...
Gene Name:
KIT
Uniprot ID:
P10721
Molecular Weight:
109863.655 Da
References
  1. Sonpavde G, Hutson TE: Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007 Mar;9(2):115-9. [PubMed:17288876 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Protein tyrosine kinase activity
Specific Function:
Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation and apoptosis. Plays an essential role in the regulation of chondrocyte differentiation, proliferation and apoptosis, and is required for normal skeleton development. Regulates both osteogenesis and postnatal bone mineraliz...
Gene Name:
FGFR3
Uniprot ID:
P22607
Molecular Weight:
87708.905 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Non-membrane spanning protein tyrosine kinase activity
Specific Function:
Tyrosine kinase that plays an essential role in regulation of the adaptive immune response. Regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. When antigen presenting cells (APC) activate T-cell receptor (TCR), a series of phosphorylation lead to the recruitment of ITK to the cell membrane, in the vicinity of the stimulated TCR recepto...
Gene Name:
ITK
Uniprot ID:
Q08881
Molecular Weight:
71830.405 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
S100 protein binding
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF1
Uniprot ID:
P05230
Molecular Weight:
17459.58 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Signaling adaptor activity
Specific Function:
Links T-cell receptor activation signal to phospholipase C-gamma-1, GRB2 and phosphatidylinositol 3-kinase.
Gene Name:
SH2B3
Uniprot ID:
Q9UQQ2
Molecular Weight:
63224.45 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357 ]
  2. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. [PubMed:20881954 ]
  3. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357 ]
  2. Goh BC, Reddy NJ, Dandamudi UB, Laubscher KH, Peckham T, Hodge JP, Suttle AB, Arumugham T, Xu Y, Xu CF, Lager J, Dar MM, Lewis LD: An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther. 2010 Nov;88(5):652-9. doi: 10.1038/clpt.2010.158. Epub 2010 Sep 29. [PubMed:20881954 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Keisner SV, Shah SR: Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011 Mar 5;71(4):443-54. doi: 10.2165/11588960-000000000-00000. [PubMed:21395357 ]
  2. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Verweij J, Sleijfer S: Pazopanib, a new therapy for metastatic soft tissue sarcoma. Expert Opin Pharmacother. 2013 May;14(7):929-35. doi: 10.1517/14656566.2013.780030. Epub 2013 Mar 14. [PubMed:23488774 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Deng Y, Sychterz C, Suttle AB, Dar MM, Bershas D, Negash K, Qian Y, Chen EP, Gorycki PD, Ho MY: Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica. 2013 May;43(5):443-53. doi: 10.3109/00498254.2012.734642. Epub 2012 Nov 16. [PubMed:23548165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Deeks ED: Pazopanib: in advanced soft tissue sarcoma. Drugs. 2012 Nov 12;72(16):2129-40. doi: 10.2165/11209950-000000000-00000. [PubMed:23072642 ]
Drug created on March 19, 2008 10:38 / Updated on July 23, 2017 12:16